ClinicalTrials.gg
Not yet recruitingNCT07662720MORALE-HN01Updated Jul 15, 2026

A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer

A Phase 1/2 interventional study of axelopran and Pembolizumab in Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), sponsored by Glycyx Therapeutics. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Glycyx Therapeutics · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This Phase 2, open-label, multicenter study will evaluate the safety and preliminary efficacy of axelopran in combination with pembrolizumab in patients with PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Axelopran is a peripherally acting mu-opioid receptor antagonist being developed to address opioid-induced immunodeficiency, a condition that may impair anti-tumor immune responses and reduce the effectiveness of immune checkpoint inhibitors.

Many patients with advanced HNSCC require opioid analgesics for cancer-related pain management. Emerging evidence suggests that opioid signaling may suppress immune function and diminish the therapeutic activity of PD-1/PD-L1 inhibitors. By blocking peripheral mu-opioid receptor signaling without affecting central analgesia, axelopran may restore immune competence and enhance response to pembrolizumab.

Approximately 18 patients with PD-L1 positive recurrent or metastatic HNSCC will be enrolled in a two-stage design consisting of an initial futility assessment cohort followed by expansion to the full study population. Participants will receive axelopran in combination with standard pembrolizumab therapy and will be followed for efficacy, safety, and survival outcomes. The estimated study duration is approximately 36 months, including enrollment, treatment, and follow-up.

The primary objectives are to evaluate objective response rate and assess the safety and tolerability of the combination regimen. Secondary and exploratory objectives include progression-free survival, overall survival, duration of response, and assessment of biomarkers related to immune activation and opioid-induced immunosuppression. This study aims to determine whether targeting opioid-mediated immune suppression can improve clinical outcomes in patients receiving immune checkpoint inhibitor therapy for advanced head and neck cancer.

02

Conditions studied

  • Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)

Keywords

  • axelopran
  • opioids
  • immuno-oncology
  • Head and Neck Squamous Cell Carcinoma (HNSCC)
  • PD-L1 Positive Tumors
  • Pembrolizumab
  • Immunotherapy
  • Opioid-Induced Immunodeficiency
  • Peripheral Mu-Opioid Receptor Antagonist
  • Immune Restoration
  • glycyx
  • MORALE-HN
03

In context

Squamous Cell Carcinoma of Head and Neck

2,020 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 574 are open to participants now.

This study's planned enrollment of 18 is below the median of 48 across 1,654 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Lead sponsor

Glycyx Therapeutics is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Individuals may be included in the trial only if they meet all of the following inclusion criteria prior to administration of product:

  1. Read, understood, and provided written and, if applicable, Health Insurance Portability and Accountability Act (HIPAA) authorization after the nature of the trial has been fully explained and must be willing to comply with all trial requirements and procedures
  2. Male or female ≥ 18 years of age
  3. Recurrent/ Squamous cell carcinoma of the head and neck (oral cavity, oropharynx, larynx, hypopharynx) that is considered incurable by local therapies, who are planning to receive pembrolizumab as therapy or for platinum failure. Platinum Failure is defined as recurrence/progression between 3-6 months from definitive platinum based chemoradiation therapy.
  4. Combined positive score (CPS) >1. PD-L1 can be done by local CLIA certified laboratory.
  5. Has not received anti-PD-1 or Anti-PD-L1 mAb therapy for recurrent/metastatic disease. A patient that received anti-PD-1 or Anti-PD-L1 mAb therapy as part of upfront curative intent therapy is eligible as long as it has been at least 1 year since the last dose of anti-PD-1 or anti-PD-L1 mAb therapy.
  6. Is taking opioid therapy to control cancer pain or will initiate opioid therapy to control cancer pain during the screening period.
  7. Has a performance status of ≤ 2 on the (ECOG) Performance Scale
  8. by v1.1 that meets the criteria for selection as a target lesion according to RECIST v1.1 (The presence of measurable disease per RECIST v1.1 must be confirmed by local radiology prior to subject entry.)
  9. Adequate organ function as defined by:

    1. Neutrophils ≥ 1,000/mm3 granulocyte colony-stimulating factor (GCSF) transfusion within 14 days prior to screening is permittable
    2. ≥ 75,000/mm3
    3. ≥ 8 g/dL
    4. (AST) or alanine aminotransferase (ALT) ≤ 2.5 × (ULN)
    5. Total \<1.5 × ULN unless known liver metastasis where allowance up to 5 × ULN will be acceptable and for those with known Gilbert's Disease where total bilirubin up to 3.0 × ULN will be acceptable
    6. Calculated ≥ 40 mL/min (Cockcroft-Gault formula) or normal creatinine.
  10. Women of (WOCBP) must have a negative serum pregnancy test prior to trial entry and must be willing to use a highly effective method of throughout the trial and trial follow up or for at least 90 days after the last dose of study intervention. NOTE: A woman is considered to be of non-childbearing potential if she meets one of the following criteria: a) with at least 12 months of spontaneous amenorrhea; b) has had a bilateral oophorectomy; or c) has had a hysterectomy.
  11. Males with female partners of childbearing potential must agree to use a highly effective method of contraception throughout the trial and trial follow up or for at least 90 days after the last dose of study intervention. All men with female partners of childbearing potential will be instructed to contact the investigator immediately if their partner becomes pregnant at any time during trial participation. All men must agree not to donate semen throughout the trial and for 90 days after the last dose of study intervention.

    -

Exclusion Criteria: Individuals will be excluded from the trial for any of the following reasons:

  1. Previous severe reaction to treatment with a monoclonal antibody, hypersensitivity to components of drug product, or has a known sensitivity to any component of the anti-PD-1 antibody (if applicable).
  2. Has received chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy that is considered to be investigational (i.e., used for nonapproved indications(s) and in the context of a research investigation) ≤ 14 days prior to the first dose of axelopran or within 5 drug half- lives (whichever is shorter) prior to the first dose of study intervention.
  3. Has received any systemic therapy for recurrent/metastatic HNSCC.
  4. Patients with any ongoing toxicity related to a prior cancer therapy that is Grade >2 and considered by the Sponsor to be a safety risk for the study will be excluded.
  5. Rapid disease progression (within or at 3 months after definitive therapy)
  6. Patients must not be under consideration for salvage surgery. This includes patients whose disease is deemed not resectable, in addition to patients who have declined salvage surgery.
  7. Has received a within 30 days of planned study intervention start Note: An individual may be eligible if they have an adequate white cell count such that an immune response can be mounted, at the discretion of the Investigator.
  8. Confirmed or active or C as determined at baseline screening.
  9. Active infection requiring anti-microbials within 2 weeks of start of trial therapy
  10. Significant cardiovascular disease including unstable angina pectoris, uncontrolled hypertension, and congestive heart failure ( (NYHA) class III or IV) related to primary cardiac disease, a history of a serious uncontrollable arrhythmia despite treatment, ischemic or severe valvular heart disease, a myocardial infarction within 6 months prior to the trial entry, or corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 msec at screening
  11. Has not fully recovered from any effects of major surgery, including complications such as infection (Surgeries that required general anesthesia must be completed ≥ 2 weeks before first study intervention administration. Surgery requiring regional/epidural anesthesia must be completed ≥ 72 hours before first study intervention administration and subjects should be recovered).
  12. Use of medications within 4 weeks, or systemic within 2 weeks prior to first dose of study intervention (Topical, inhaled, or intranasal corticosteroids [with minimal systemic absorption] may be continued if the individual is on a stable dose. Non-absorbed intra-articular corticosteroid and replacement steroids [prednisone equivalent 10 mg or less] will be permitted.)
  13. Underlying medical condition that, in the investigator's opinion, will make the administration of study intervention hazardous or obscure the interpretation of toxicity determination or AEs
  14. Women who are pregnant or breastfeeding
  15. Known alcohol or drug abuse or dependence
  16. Subjects with known or suspected mechanical gastrointestinal obstruction and at increased risk of recurrent obstruction (i.e., Crohn's disease, peptic ulcer disease, Ogilvie's syndrome, diverticular disease, infiltrative gastrointestinal tract or peritoneal metastases).
  17. Subjects with moderate or severe renal impairment ( \<60) or moderate and severe hepatic impairment ( Band C).
  18. Subjects taking moderate to strong inhibitors or P-gp inhibitors (see List in Appendix 5)

    -

Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Axelopran in combination with Pembrolizumab in PDL-1 positive patients with HNSCC

    Drug: axelopran · Drug: Pembolizumab

Interventions

  • Axelopran is a investigational, orally administered, once daily, peripherally acting mu-opioid receptor antagonist administered in combination with pembrolizumab in patients with PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).

    Also known as: TD-1211, pembrolizumab

  • Pembrolizumab will be given every 6 weeks for 18 cycles

    Also known as: Keytruda, pembro

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability

    To assess the safety of daily axelopran in combination with standard of care pembrolizumab in the first line treatment of R/M HNSCC patients with PD-L1 CPS ≥1 receiving opioids for pain control over a 12-week period.

    Time frame: 12 weeks

Secondary outcomes

  1. Spontaneous bowel motility (SBM)

    To evaluate SBM number and form associated with cancer progression outcome

    Time frame: 5 and 12 weeks

  2. Overall Response Rate (ORR)

    ORR by investigator assessment based on RECIST v1.1, to assess efficacy by Objective Response Rate (ORR), per Response Evaluation Criteria in Solid Tumors (RECIST) with pembrolizumab plus axelopran

    Time frame: Approximately 18 months

  3. Duration of Response (DOR)

    To evaluate Duration of Response (DOR), time from start of treatment to disease progression or death in patients who achieve CR or PR per RECIST v1.1.

    Time frame: Approximately 18 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Aug 2027, 13 months later.

Of 93 industry-sponsored phase 1/2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 78. This study's planned 13 months is below that.

Counting every sponsor, half of 138 studies reached it within 61 months; a quarter within 47 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2026
First posted
Jun 23, 2026
StartEst.
Jul 15, 2026
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2028
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07662720
Lead sponsor
Glycyx Therapeutics
Responsible party
Sponsor
First posted
Jun 23, 2026
Start date
Jul 15, 2026 (estimated)
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Jul 15, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axelopran

Start the discussion